WO2007012838A3 - Drug delivery system - Google Patents
Drug delivery system Download PDFInfo
- Publication number
- WO2007012838A3 WO2007012838A3 PCT/GB2006/002772 GB2006002772W WO2007012838A3 WO 2007012838 A3 WO2007012838 A3 WO 2007012838A3 GB 2006002772 W GB2006002772 W GB 2006002772W WO 2007012838 A3 WO2007012838 A3 WO 2007012838A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- drug
- delivery system
- drug delivery
- drug carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Abstract
The invention relates to peptides and peptide analogues/derivatives, for use as peptide drug carrier molecules, and peptide drug carrier-drug conjugates which are transported across the wall of the gut into the blood by PepTl protein. There is provided a drug carrier comprising a peptide, or derivative or analogue thereof, the peptide comprising at least two amino acid residues linked by a peptide bond. The amino acid residues are arranged such that the peptide bond is protected from hydrolysis. The peptide comprises a functional group for attachment to a drug. The functional group to which the drug is attached is provided on the second or C-terminal residue of the peptide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0515363.0A GB0515363D0 (en) | 2005-07-27 | 2005-07-27 | Drug delivery system |
GB0515363.0 | 2005-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007012838A2 WO2007012838A2 (en) | 2007-02-01 |
WO2007012838A3 true WO2007012838A3 (en) | 2007-05-03 |
Family
ID=34976643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2006/002772 WO2007012838A2 (en) | 2005-07-27 | 2006-07-25 | Drug delivery system |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0515363D0 (en) |
WO (1) | WO2007012838A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017156648A1 (en) * | 2016-03-18 | 2017-09-21 | 广州诺威生物技术有限公司 | Compound having anti-inflammatory effect |
CN106279353A (en) * | 2016-03-18 | 2017-01-04 | 广州诺威生物技术有限公司 | A kind of compound for antiinflammatory |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
-
2005
- 2005-07-27 GB GBGB0515363.0A patent/GB0515363D0/en not_active Ceased
-
2006
- 2006-07-25 WO PCT/GB2006/002772 patent/WO2007012838A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
Non-Patent Citations (4)
Title |
---|
BRODIN BIRGER; NIELSEN CARSTEN UHD; STEFFANSEN BENTE; FROKJAER SVEN: "Transport of peptidomimetic drugs by the intestinal Di/tri-peptide transporter, PepT1", PHARMACOLOGY & TOXICOLOGY, vol. 90, no. 6, June 2002 (2002-06-01), pages 285 - 296, XP002403283 * |
LEPIST E I; KUSK T; LARSEN D H; ANDERSEN D; FROKJAER S; TAUB M E; VESKI P; LENNERNÄS H; FRIEDRICHSEN G; STEFFANSEN B: "Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 11, no. 1, July 2000 (2000-07-01), pages 43 - 50, XP002403282 * |
TAUB M E; DUE LARSEN B; STEFFANSEN B; FROKJAER S: "[beta]-Carboxylic acid esterified D-Asp-Ala retains a high affinity for the oligopeptide transporter in Caco-2 monolayers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 146, no. 2, 15 January 1997 (1997-01-15), pages 205 - 212, XP002403281 * |
THOMSEN AE; FRIEDRICHSEN GM; SORENSEN AH; ANDERSEN R; NIELSEN CU; BRODIN B; EGTRUP M; FROKJAER S; STEFFANSEN B: "Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism", JOURNAL OF CONTROLLED RELEASE, vol. 86, no. 2-3, 17 January 2003 (2003-01-17), pages 279 - 292, XP004401122 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007012838A2 (en) | 2007-02-01 |
GB0515363D0 (en) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ahrens et al. | Peptides and peptide conjugates: therapeutics on the upward path | |
WO2006031811A3 (en) | Glycopegylated interferon alpha | |
Nolan et al. | Applications of thiol-ene chemistry for peptide science | |
JP5209463B2 (en) | Acylated GLP-1 compounds | |
JP5755398B2 (en) | Elongated GLP-1 compound | |
EP2717898B1 (en) | Pro-coagulant compounds and methods of use thereof | |
WO2005056760A3 (en) | Glycopegylated follicle stimulating hormone | |
CA2651990C (en) | Improved antimicrobial peptides | |
WO2007022512A3 (en) | Glycopegylated factor vii and factor viia | |
WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
MX2010002460A (en) | Complexes of rna and cationic peptides for transfection and for immunostimulation. | |
WO2006127896A3 (en) | Glycopegylated factor ix | |
WO2005055950A3 (en) | Glycopegylated factor ix | |
WO2006074467A3 (en) | Glycopegylated granulocyte colony stimulating factor | |
JP2002530430A (en) | Pharmaceutical composition for inhibiting hepatitis C virus NS3 protease | |
JP7250814B2 (en) | Novel GLP-1 analogues | |
MX2009002999A (en) | Protease resistant insulin analogues. | |
WO2007096662A3 (en) | Cancer imaging and treatment | |
WO2008081701A1 (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
WO2006119388A3 (en) | Methods for the production of peptide having a c-terminal amide | |
WO2008098749A3 (en) | Peptides derived from the major allergen of ragweed (ambrosia artemisiifolia) and uses thereof | |
JP2011518179A5 (en) | ||
MX2009013635A (en) | Influenza inhibiting compositions and methods. | |
WO2007144198B1 (en) | Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases | |
EP2039367A4 (en) | Prophylactic/therapeutic agent for neurodegenerative disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06765097 Country of ref document: EP Kind code of ref document: A2 |